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INTRODUCTION
Heparin-induced thrombocytopaenia (HIT) is an acquired 
thrombophilia associated with high risk of venous throm-
boembolism (VTE) and arterial thrombosis, largely caused 
by platelet-activating immunoglobulin G (IgG) antibodies 
against platelet factor (PF)4/heparin complexes [1]. Unfrac-
tionated heparin (UFH) is more likely, compared with low- 
-molecular-weight heparins (LMWH), to provoke synthesis of 
anti-PF4/heparin antibodies, with the highest risk following 
cardiac surgery with extracorporeal circulation [2]. The 4Ts 
scoring system, incorporating four typical features of HIT 
(magnitude of thrombocytopaenia, timing with respect to 
heparin exposure, thrombosis, and other causes of thrombocy-
topaenia) is commonly used to assess the pre-test probability 
of HIT [3]. The diagnostic pathway involves high-sensitivity 
tests, e.g. enzyme-immunoassays (EIAs), followed by con-
firmatory platelet activation assays (serotonin-release assay 
[SRA] and/or heparin-induced platelet activation [HIPA]) [4]. 
To our knowledge, very few case reports have described Polish 
patients with HIT, with no cases including subjects undergo-
ing cardiac surgery [5]. We sought to assess the prevalence 
of anti-PF4/heparin IgG antibodies in the first series of Polish 
patients undergoing cardiac surgery versus other patients 
suspected of HIT. 
METHODS
We performed a retrospective study of patients suspected 
of HIT, tested at the John Paul II Hospital, Krakow, Poland, 
between January 2012 and July 2017. Patients provided 
written consent to use their data. The Hospital Bioethical 
Committee was informed about the study. Demographic 
and clinical data, including 4Ts scores [6], were analysed. 
The anti-PF4/heparin IgG antibodies were determined by 
EIA test (Immucor GTI Diagnostics, Waukesha, WI, USA), 
with confirmation using excess heparin (100 U/mL), follow-
ing the manufacturer’s instructions. All patients with optical 
density (OD) values ≥ 0.4 and inhibition of a positive reaction 
by ≥ 50% in the presence of excess heparin were deemed 
positive for PF4/heparin antibodies [7]. 
Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation or median and interquartile range. Normality was 
assessed by the Shapiro-Wilk test. Groups were compared us-
ing the Student t test or Mann-Whitney U test, as appropriate. 
Categorical variables were presented as numbers (percent-
ages) and compared using the Pearson’s c2 test or the Fisher 
exact test if 20% of cells had an expected count of less than 
five. Two-sided p-values < 0.05 were considered statistically 
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significant. Analyses were performed with Statistica (v. 13.1, 
StatSoft, Inc, Tulsa, OK, USA) and JMP® version 14.0.0 (SAS 
Institute Inc., Cary, NC, USA).
RESULTS AND DISCUSSION
A total of 255 tests were performed in 236 patients. Due 
to incomplete data, the final analysis was performed in 
122 (51.7%) patients (Table 1), with similar age and sex dis-
tribution as the remainder. The cardiac surgery group with 
extracorporeal circulation (n = 39, 32%) comprised patients 
after the following procedures: aortic valve replacement 
(n = 27, 69.2%), mitral valve replacement (n = 3, 7.7%), 
coronary artery bypass grafting (n = 3, 7.7%), heart trans-
plantation (n = 3, 7.7%), and other surgeries (n = 3, 7.7%). 
A reference group comprised 39 (47.0%) medical patients, 
16 (19.3%) subjects following non-cardiac surgery, 16 (19.3%) 
after percutaneous angioplasty, five (6.0%) after aortic stent 
graft implantation, and seven (8.4%) after other procedures. 
The cardiac surgery group, in which all patients received 
UFH followed by LMWH, experienced greater median plate-
let fall compared with the reference group, mainly receiving 
LMWH, with no intergroup difference in the median time 
from heparin therapy onset to the platelet fall (Table 1). 
The proportion of patients with positive anti-PF4/heparin 
antibodies was comparable in both groups (10 [25.6%] 
vs. 24 [28.9%], p = 0.7), and the former value was similar 
compared with the rate reported recently [8]. The median 
OD value among patients positive for the anti-PF4/heparin 
IgG antibodies was 2.94 (0.69–3.90) in the cardiac surgery 
group and 1.70 (1.06–3.26) in the reference group (p > 0.05). 
A previous report showed that replacing UFH with LMWH 
decreases levels of anti-PF4/heparin antibodies [9]. Contrary 
to earlier studies [10], in our study the prevalence of positive 
anti-PF4/heparin IgG antibodies was similar in the cardiac 
surgery group and the reference group, probably due to 
a postoperative conversion from UFH to LMWH soon after 
the surgery. The reference group included patients treated for 
acute coronary syndrome, among whom UFH is still a more 
frequently used anticoagulant than LMWH [11]. 
The proportion of positive results according to the hepa-
rin type was: UFH, 9.0%; LMWH, 25.5%; and both agents, 
33.3%. Enoxaparin (n = 84, 68.9%) was the most commonly 
used LMWH, as reported in various Polish patients [12], fol-
lowed by nadroparin (n = 11, 9.0%), dalteparin (n = 6, 4.9%), 
and two different LMWHs used during therapy (n = 3, 3.6%); 
in seven (5.7%) patients a LMWH was unspecified. 
Table 1. Comparison of patients following cardiac surgery and other patients
Variable All patients 
(n = 122, 100%)
Patients following  
cardiac surgery  
(n = 39, 32%)
Other patients 
(n = 83, 68%)
p
Age [years] 66.5 (55–75) 67 (54–76) 66 (56–74) 0.9
Male sex 75 (61.5) 26 (66.7) 49 (59.0) 0.4
Heparin exposure and platelet fall
Heparin type: < 0.001
Low-molecular-weight heparin 51 (41.8) 0 (0) 51 (61.4)
Unfractionated heparin 11 (9.0) 0 (0) 11 (13.3)
Both agents 60 (49.2) 39 (100) 21 (25.3)
Platelet count fall [%] 59.3 (44.2–77.5) 67.5 (53.8–83.2) 57.6 (42.3–76.2) 0.04
Time from introducing heparin to platelet fall [days] 6 (3–11) 6 (4-11) 7 (3-11) 0.6
Anti-PF4-heparin IgG EIA result*:
≥ 0.4 OD 37 (30.3) 10 (25.6) 27 (32.5) 0.4
≥ 1.0 OD 27 (22.1) 7 (18.0) 20 (24.1) 0.4
≥ 2.0 OD 19 (15.6) 6 (15.4) 13 (15.7) 1.0
4Ts score: 0.003
≤ 3 points 72 (59.0) 29 (74.4) 43 (51.8)
4–5 points 36 (29.5) 10 (25.6) 26 (31.3)
≥ 6 points 14 (11.5) 0 (0) 14 (16.9)
Data are presented as number (percentage) or median (interquartile range). Groups were compared using Mann-Whitney U test for continuous 
variables, Fisher exact test for 2 × 2 tables and c2 test for other tables. IgG — immunoglobulin G; EIA — enzyme-immunoassays; OD — optical 
density; PF — platelet factor
*Three participants with OD ≥ 0.4 were not inhibited by high heparin, and thus 34 (27.9%) patients were considered positive for  
anti-PF4/heparin IgG EIA
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Patients in the cardiac surgery group were less likely to 
have four points or more in 4Ts score compared with the refer-
ence group (10 [25.6%] vs. 40 [48.2%], p = 0.02), confirming 
the clinical relevance of this scoring system [3]. 
Fondaparinux was the most common non-heparin al-
ternative (n = 19, 55.9%) among our patients with positive 
anti-PF4/heparin antibodies following heparin withdrawal, as 
it was among anticoagulants used off-label in Germany [13]. 
Other anticoagulants used in our cohort following positive 
results were bivalirudin (n = 1, 2.9%), vitamin K antagonists 
(n = 3, 8.8%), and rivaroxaban (n = 1, 2.9%), although the use 
of oral anticoagulants is contraindicated in patients suspected 
of HIT if the platelet count is low [14]; other non-heparin 
alternatives were unspecified. Argatroban was not used in 
any patient. 
We identified 21 (17.2%) thromboembolic events, 
including 12 (57.1%) VTEs, six (28.6%) arterial thromboses, 
and three (14.1%) cases of acral necrosis, all of which oc-
curred in the reference group. Among those 21 patients, 
there were more patients with OD ≥ 0.4, as compared 
with patients without thromboembolic events (14 [66.7%] 
vs. 23 [22.7%], p < 0.001). Similar observations held true 
for OD ≥ 1.0 (13 [61.9%] vs. 14 [13.9%], p < 0.001) and 
OD ≥ 2.0 (9 [42.9%] vs. 10 [9.9%], p < 0.001), respectively. 
The most unusual patient in our series was a 31-year-old 
obese woman, with prior deep vein thrombosis at the age of 
18 years while on oral contraceptives, with no family history 
of VTE, who was diagnosed with left iliofemoral thrombo-
sis in the 10th week of her second pregnancy. After three 
days of UFH therapy followed by the use of enoxaparin for 
32 days, progression of the disease and a decrease in plate-
let count from 337 × 109/L to 38 × 109/L (reference range, 
140–440 × 109/L) were noted. As shown in Supplemental 
Figure 1 (see journal website), the diagnosis of HIT was 
supported by highly elevated anti-PF4/heparin IgG antibod-
ies. Fondaparinux 7.5 mg/d was initiated, and platelet count 
normalised. Thrombophilia screening showed a heterozygous 
factor V Leiden mutation. Pregnancy failed at the 24th week. 
Later, warfarin was introduced, and anticoagulation was sta-
ble. Unexpectedly, anti-PF4/heparin IgG antibodies remained 
elevated in the subsequent 4.5 years, exceeding 90 days to 
a negative test observed in most patients with HIT [15]. The 
HIPA test confirmed HIT-specific antibodies and their absence 
when the antibody test yielded a negative result (Suppl. Fig. 1 
— see journal website). It is known that in the EIA test the 
OD values between 0.4 and 1.0 are weakly associated with 
positive functional test results, while OD values ≥ 2.0 corre-
spond to a > 90% probability of SRA [3]. This case strongly 
encourages the use the SRA or HIPA tests to confirm HIT, 
especially if OD values are below 1. 
The study limitations involve shortcomings typical of 
retrospective design and a lack of results of specific tests for 
all patients with elevated OD. The study strength lies in the 
fact that it is the first analysis of consecutive patients suspected 
of HIT referred for laboratory work-up in Poland, which 
confirms the need for a wider availability of specific tests to 
confirm positive anti-PF4/heparin antibodies, given the high 
proportion of negative final results at low 4Ts scores. This 
study supports rapid initiation of LMWH after cardiac surgery 
to reduce the risk of HIT and its life-threatening sequalae. 
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